HOME Sitemap Contact Us
About HanmiKorea Hanmi

Our Hanmi

Korea Hanmi Group

Korea Hanmi Group (hereinafter referred to as Hanmi Group) was founded by Mr. Sheng-ji Lin in 1973 and is headquartered in Seoul, Korea. It adheres to the operation philosophy of Human Respect and Value Creation, is dedicated to the research and development of prescription drugs, owns more than 280 patented technologies and takes a leading position in many fields such as antibiotics, cardiovascular diseases, digestion, antineoplastics and pediatrics. Hanmi Group provides more than 200 drugs for global clinical treatment, sells patented and transferred technologies to internationally known drug manufacturers such as Roche and Novartis and becomes a global famous pharmaceutical expert by means of its world leading scientific technologies, advanced equipment and drugs with significant curative effects. Hanmi Group also owns subsidiaries such as Fine Chemicals, Giheung Research Institute, Pyeongtaek Antibiotic Factory and Medicare, which lays a solid foundation for its research and development, production and sales, and develops into an international specialized pharmaceutical enterprise through foreign subsidiaries in China, Japan and Britain.

Hanmi Group develops and researches Korean domestic new drug products through two high-quality research and development technologies namely long-acting protein/polypeptide drug technology (LAPSCOVERY) and oral drug technology (ORASCOVERY) as the core. The company owns more than 200 excellent products in various fields such as antibiotics, cardiac diseases, digestion and antineoplastics.

Hanmi Group has gained numerous honors in the development history, including Korea Best Corporate Award, Most Trustworthy Corporate Award, Best Employer, Asia’s Best CEO, Best Drug Research Award presented by Korea Drug Research Association (KDRA), New Technology Award presented by Ministry of Knowledge Economy (MKE) and Korea Institute For Advancement of Technology (KIAT) and Korea Excellent Technology Award.

Through constant development in recent decades, Hanmi Group has maintained robust growth in scale and sales achievement and made significant contribution to global medicine field. Besides Korean headquarters, Hanmi Group also possesses drug research center and many production bases, and overseas establishments spread all over many countries and regions including China, Japan and Europe. The future vision of Hanmi Group is to break through $1 billion overseas sales in 2015 and reach $3 billion overseas sales in 2020.